AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20070758 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ball-type mini-implants (Group I)
Number of subjects: 45
Study 20070758 — intervention group
Group type: COMPARATOR
Intervention: Mini-implants splinted with a prefabricated bar (Group II)
Number of subjects: 45
Study 19000365 — intervention group
Group type: COMPARATOR
Intervention: MDI (Metered Dose Inhaler)
Number of subjects: 13
Study 19000365 — intervention group
Group type: EXPERIMENTAL
Intervention: VOL (Volumatic spacer)
Number of subjects: 13
Study 19000365 — intervention group
Group type: EXPERIMENTAL
Intervention: AERO (Aerochamber Plus spacer)
Number of subjects: 13
Study 19000365 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of VOL and AERO
Number of subjects: 13
Study 16186088 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral drug abuse therapies
Number of subjects: 162
Study 12966284 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective multidisciplinary information session 2 to 6 weeks before surgery
Number of subjects: 100
Study 12966284 — intervention group
Group type: COMPARATOR
Intervention: Usual verbal information (Control)
Number of subjects: 100
Study 10571351 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty and topical betaxolol twice daily in eligible eyes
Number of subjects: 255
Study 10571351 — intervention group
Group type: COMPARATOR
Intervention: No initial treatment with close follow-up
Number of subjects: 255
Study 9339040 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral and corneal tunnel incisions (6.0‐mm W; 3.5‐ and 2.5‐mm L scleral tunnel; 4.1‐mm linear and 2.5‐mm L corneal tunnel)
Number of subjects: 0
Study 9339040 — intervention group
Group type: COMPARATOR
Intervention: Control group of nonoperated eyes
Number of subjects: 0
Study 2643357 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment plus a fixed schedule of nicotine gum
Number of subjects: 89
Study 2643357 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment plus an ad lib schedule
Number of subjects: 89
Study 2643357 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus a fixed schedule
Number of subjects: 89
Study 2643357 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus an ad lib schedule
Number of subjects: 89
Study 2643357 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 89
Study 2643357 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 89
Study 1259398 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxolinic acid (1.5 g twice daily by mouth for 5 to 12 days)
Number of subjects: 7
Study 1259398 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (after patient was changed from oxolinic acid)
Number of subjects: 7
Study 1259398 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (3 patients responded to this treatment)
Number of subjects: 7
Study 1259398 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxolinic acid
Number of subjects: 7
Study 29739680 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium bicarbonate supplementation (90 mmol × d−1)
Number of subjects: 0
Study 28372647 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (5μg/kg/min)
Number of subjects: 40
Study 28372647 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study 26100002 — intervention group
Group type: EXPERIMENTAL
Intervention: HP gel + KTP laser irradiation
Number of subjects: 36
Study 26100002 — intervention group
Group type: EXPERIMENTAL
Intervention: HP gel + Er:YAG irradiation
Number of subjects: 36
Study 26100002 — intervention group
Group type: COMPARATOR
Intervention: HP gel without laser irradiation
Number of subjects: 36
Study 23330721 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-bp insertion/deletion polymorphism of HLA-G gene (dominant model)
Number of subjects: 1464
Study 23330721 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-bp insertion/deletion polymorphism of HLA-G gene (codominant model)
Number of subjects: 1464
Study 23330721 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-bp insertion/deletion polymorphism of HLA-G gene (dominant model after sensitivity analysis)
Number of subjects: 1464
Study 23330721 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-bp insertion/deletion polymorphism of HLA-G gene (codominant model after sensitivity analysis)
Number of subjects: 1464
Study 21485673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 100
Study 21485673 — intervention group
Group type: COMPARATOR
Intervention: Oral paracetamol
Number of subjects: 100
Study 19910649 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (45 min cycling at 65% heart-rate reserve)
Number of subjects: 20
Study 19910649 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 20
Study 21735073 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressed smoking thoughts
Number of subjects: 0
Study 21735073 — intervention group
Group type: COMPARATOR
Intervention: Expressed smoking thoughts
Number of subjects: 0
Study 21735073 — intervention group
Group type: COMPARATOR
Intervention: Thinking about anything they wished
Number of subjects: 0
Study 15821499 — intervention group
Group type: EXPERIMENTAL
Intervention: RTX 0.01 microM
Number of subjects: 163
Study 15821499 — intervention group
Group type: EXPERIMENTAL
Intervention: RTX 0.05 microM
Number of subjects: 163
Study 15821499 — intervention group
Group type: EXPERIMENTAL
Intervention: RTX 0.10 microM
Number of subjects: 163
Study 15821499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 12057987 — intervention group
Group type: EXPERIMENTAL
Intervention: 192Ir (catheter-based iridium-192)
Number of subjects: 55
Study 12057987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9843465 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 103
Study 9843465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 8005898 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD group
Number of subjects: 79
Study 8005898 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 79
Study 2492597 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk preparation (14 mL/kg/d for 2 weeks)
Number of subjects: 16
Study 2492597 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (14 mL/kg/d for 2 weeks)
Number of subjects: 16
Study 133841 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 19
Study 133841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17-butyrate (HC 17-B)
Number of subjects: 19
Study 133841 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 19
Study 29927279 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Tolerance (DT) treatment
Number of subjects: 116
Study 29927279 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 116
Study 29927279 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DT and ST treatments included transdermal nicotine patch and structured sessions.
Number of subjects: 116
Study 27033012 — intervention group
Group type: EXPERIMENTAL
Intervention: tVNS (25 Hz)
Number of subjects: 76
Study 27033012 — intervention group
Group type: COMPARATOR
Intervention: Control (1 Hz)
Number of subjects: 76
Study 24731061 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary alveolar bone graft (SABG)
Number of subjects: 50
Study 22460472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistive exercise (n = 8)
Number of subjects: 24
Study 22460472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistive exercise with whole-body vibration (n = 9)
Number of subjects: 24
Study 22460472 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control, n = 9)
Number of subjects: 24
Study 20542239 — intervention group
Group type: EXPERIMENTAL
Intervention: Long feedback from computerized alcohol intervention
Number of subjects: 0
Study 20542239 — intervention group
Group type: EXPERIMENTAL
Intervention: Short feedback from computerized alcohol intervention
Number of subjects: 0
Study 20542239 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized intervention overall
Number of subjects: 0
Study 18502363 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmarch bandage
Number of subjects: 70
Study 18502363 — intervention group
Group type: COMPARATOR
Intervention: Limb elevation
Number of subjects: 70
Study 15952627 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride drop group
Number of subjects: 1200
Study 15952627 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste group
Number of subjects: 1200
Study 15952627 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1200
Study 11910265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50‐200 mg/day)
Number of subjects: 42
Study 11910265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10515247 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD30
Number of subjects: 10
Study 10515247 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL-2R
Number of subjects: 10
Study 10515247 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra
Number of subjects: 10
Study 7728829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dentifrice with fluoride
Number of subjects: 10
Study 7728829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dentifrice without fluoride
Number of subjects: 10
Study 7728829 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 10
Study 2109464 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (n = 40)
Number of subjects: 80
Study 2109464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 80
Study 7390376 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramal
Number of subjects: 23
Study 7390376 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 23
Study 31230464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 55
Study 31230464 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (control)
Number of subjects: 55
Study 28658162 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual recipes developed by a multidisciplinary team (nurses, doctors, dietitian, caregivers)
Number of subjects: 110
Study 28658162 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 110
Study 26651467 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min after 30 SB min
Number of subjects: 30
Study 26651467 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 min after 60 SB min
Number of subjects: 30
Study 26651467 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 min after 120 SB min
Number of subjects: 30
Study 24117926 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded evaluation of dermal changes in BCC
Number of subjects: 301
Study 24117926 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded evaluation of dermal changes in MIS
Number of subjects: 301
Study 24117926 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded evaluation of dermal changes in AK
Number of subjects: 301
Study 24117926 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall blinded evaluation of dermal changes
Number of subjects: 301
Study 21474477 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical incident scenarios
Number of subjects: 15
Study 21474477 — intervention group
Group type: COMPARATOR
Intervention: Uneventful anaesthesia induction
Number of subjects: 15
Study 21474477 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical incident scenarios (experienced anaesthetists)
Number of subjects: 15
Study 21474477 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical incident scenarios (less experienced anaesthetists)
Number of subjects: 15
Study 19164205 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib 150 mg
Number of subjects: 57
Study 19164205 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 300 mg
Number of subjects: 57
Study 17364629 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of superactivated charcoal (50 g)
Number of subjects: 1103
Study 17364629 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of superactivated charcoal (50 g, six doses q4h)
Number of subjects: 1103
Study 14680739 — intervention group
Group type: EXPERIMENTAL
Intervention: bucindolol
Number of subjects: 2708
Study 14680739 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2708
Study 11075558 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) group
Number of subjects: 20
Study 11075558 — intervention group
Group type: COMPARATOR
Intervention: Conventional continuous infusion (Cont group)
Number of subjects: 20
Study 9176446 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyometrial ET
Number of subjects: 40
Study 9176446 — intervention group
Group type: COMPARATOR
Intervention: Transcervical ET
Number of subjects: 40
Study 1300957 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (30 mu in 5 mn)
Number of subjects: 183
Study 1300957 — intervention group
Group type: COMPARATOR
Intervention: rt PA (10 mg bolus followed by 90 mg in 130 mn)
Number of subjects: 183
Study 3840066 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine (BW825C) 4 mg, 8 mg, and 16 mg
Number of subjects: 12
Study 3840066 — intervention group
Group type: COMPARATOR
Intervention: Triprolidine HCl 2.5 mg and 5 mg
Number of subjects: 12
Study 3840066 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine (BW825C)
Number of subjects: 12
Study 30648677 — intervention group
Group type: EXPERIMENTAL
Intervention: GA + caudal epidural analgesia (Group I)
Number of subjects: 50
Study 30648677 — intervention group
Group type: COMPARATOR
Intervention: GA + intravenous analgesia (Group II)
Number of subjects: 50
Study 30098042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimodivir 600 mg with oseltamivir 75 mg
Number of subjects: 34
Study 30098042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimodivir 600 mg
Number of subjects: 34
Study 30098042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 27086671 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan
Number of subjects: 60
Study 27086671 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 60
Study 24874893 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 79
Study 24874893 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (dose-escalation subcohort)
Number of subjects: 79
Study 23101763 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cardiovascular case finding in intervention practices
Number of subjects: 6250
Study 23101763 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 6250
Study 20598967 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel + aspirin
Number of subjects: 10300
Study 20598967 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel + aspirin
Number of subjects: 10300
Study 18612426 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg of Pfs25/ISA 51
Number of subjects: 36
Study 18612426 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg of Pvs25/ISA 51
Number of subjects: 36
Study 18612426 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg of Pvs25/ISA 51
Number of subjects: 36
Study 18612426 — intervention group
Group type: COMPARATOR
Intervention: PBS/ISA 51 (adjuvant control)
Number of subjects: 36
Study 15818103 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (6 mL/kg of predicted body weight)
Number of subjects: 61
Study 15818103 — intervention group
Group type: COMPARATOR
Intervention: Higher tidal volume ventilation (12 mL/kg of predicted body weight)
Number of subjects: 61
Study 15818103 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation
Number of subjects: 61
Study 15818103 — intervention group
Group type: COMPARATOR
Intervention: Higher tidal volume ventilation
Number of subjects: 61
Study 12596573 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anaesthesia (CSE), n = 20
Number of subjects: 40
Study 12596573 — intervention group
Group type: COMPARATOR
Intervention: Balanced general anaesthesia (BGA) with controlled ventilation, n = 20
Number of subjects: 40
Study 9787651 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention aimed at lifestyle changes in diet and physical activity
Number of subjects: 489
Study 9787651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 489
Study 7634133 — intervention group
Group type: EXPERIMENTAL
Intervention: Delmopinol hydrochloride solution (2 mg/ml) rinsing for 60 s twice daily
Number of subjects: 14
Study 7634133 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinsing
Number of subjects: 14
Study 2792175 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin and concomitant treatment with urapidil 60 mg b.d.
Number of subjects: 12
Study 2792175 — intervention group
Group type: COMPARATOR
Intervention: digoxin monotherapy
Number of subjects: 12
Study 356508 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam in polyethyleneoxydricinolate vehicle (Group A)
Number of subjects: 35
Study 356508 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam in propyleneglycol‐ether alcohol vehicle (Group B)
Number of subjects: 35
Study 356508 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam combined with intramuscular administration of vehicle used in Group B (Group C)
Number of subjects: 35
Study 30964804 — intervention group
Group type: EXPERIMENTAL
Intervention: Condoms
Number of subjects: 611
Study 30964804 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 611
Study 29668726 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-to-music video program (8 weeks)
Number of subjects: 71
Study 27066730 — intervention group
Group type: EXPERIMENTAL
Intervention: PST + PE
Number of subjects: 94
Study 27066730 — intervention group
Group type: EXPERIMENTAL
Intervention: PST
Number of subjects: 94
Study 27066730 — intervention group
Group type: COMPARATOR
Intervention: EUC
Number of subjects: 94
Study 24461403 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA apical plug
Number of subjects: 36
Study 24461403 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic protocol (blood clot)
Number of subjects: 36
Study 24461403 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic protocol (blood clot + injectable scaffold)
Number of subjects: 36
Study 22261128 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1 capsule daily for 3 months)
Number of subjects: 95
Study 22261128 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 months)
Number of subjects: 95
Study 20039078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg(‐1)
Number of subjects: 45
Study 20039078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.0 mg kg(‐1)
Number of subjects: 45
Study 20039078 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study 20039078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (both doses)
Number of subjects: 45
Study 17621653 — intervention group
Group type: EXPERIMENTAL
Intervention: GuardWire Plus
Number of subjects: 341
Study 17621653 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 341
Study 16353968 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelled self-emulsifying formulation (SEF) containing ketoprofen (KPF)
Number of subjects: 0
Study 16353968 — intervention group
Group type: COMPARATOR
Intervention: Immediate release solid dosage form
Number of subjects: 0
Study 12559482 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) 0.08 U/kg IM
Number of subjects: 40
Study 12559482 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose physostigmine (PHYSO) 8 microg/kg IV
Number of subjects: 40
Study 12559482 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 40
Study 12559482 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma leptin concentrations
Number of subjects: 40
Study 9848316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystectomy of the endometrioma (group 1)
Number of subjects: 64
Study 9848316 — intervention group
Group type: COMPARATOR
Intervention: Drainage of the endometrioma and bipolar coagulation of the inner lining (group 2)
Number of subjects: 64
Study 8008533 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 83
Study 8008533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 8008533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Simethicone and Placebo
Number of subjects: 83
Study 2480243 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (IFN)
Number of subjects: 20
Study 2480243 — intervention group
Group type: COMPARATOR
Intervention: Streptozocin plus 5‐fluorouracil (chemotherapy)
Number of subjects: 20
Study 19155900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical vasopressin (8 units)
Number of subjects: 58
Study 19155900 — intervention group
Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 58
Study 229780 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) for 28 days
Number of subjects: 28
Study 229780 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) for less than 9-14 days
Number of subjects: 28
Study 229780 — intervention group
Group type: COMPARATOR
Intervention: Intensive Nutritional Counseling (INC) and oral supplementation
Number of subjects: 28
Study 31868126 — intervention group
Group type: EXPERIMENTAL
Intervention: Agency assigned to the virus
Number of subjects: 0
Study 31868126 — intervention group
Group type: EXPERIMENTAL
Intervention: High marking of argumentative orientation
Number of subjects: 0
Study 31868126 — intervention group
Group type: COMPARATOR
Intervention: Agency assigned to humans
Number of subjects: 0
Study 31868126 — intervention group
Group type: COMPARATOR
Intervention: Low marking of argumentative orientation
Number of subjects: 0